Several studies have proposed that the PPARγ agonist troglitazone induces intrahepatic cholestasis via the inhibition of ABCB11, potentially contributing to hepatotoxicity [47, 48]. The gene discussed is ABCB11; the disease is intrahepatic cholestasis.